Francesca Zanghì
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Francesca Zanghì has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Carlo Alberto Giorgi
Istituto Oncologico Veneto 2 Division of Oncology 2, IRCCS, Padova, Italy
7 shared publications - Christine Hodgdon
GRASP, Baltimore, Maryland
7 shared publications - Cristina Falci
Division of Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS , Padua 35128
7 shared publications - Federica Miglietta
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy
7 shared publications - Francesca Caumo
Istituto Oncologico Veneto 5 Radiology Unit, IRCCS, Padova, Italy
7 shared publications - Gaia Griguolo
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
7 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Cumulative incidence curves for diagnosis of brain metastases (A), diagnosis of symptomatic brain metastases (B), and diagnosis of asymptomatic brain metastases (C) according to brain screening practice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Cumulative incidence curves for diagnosis of brain metastases (A), diagnosis of symptomatic brain metastases (B), and diagnosis of asymptomatic brain metastases (C) according to brain screening practice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Clinical characteristics at brain metastasis diagnosis and first treatments received (locoregional and systemic) after brain metastasis diagnosis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Clinical characteristics at brain metastasis diagnosis and first treatments received (locoregional and systemic) after brain metastasis diagnosis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Clinicopathologic characteristics at breast cancer diagnosis and at mBC diagnosis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Clinicopathologic characteristics at breast cancer diagnosis and at mBC diagnosis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Purpose:According to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC) because of high risk of developing brain metastases. However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic brain metastases in patients with HER2+ mBC.Experimental Design:Consecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab–pertuzumab plus taxane (2014–2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurologic symptoms during the first 2 years after diagnosis.Results:Among 148 identified patients, 73 underwent brain screening and 75 did not. The median number of annual brain CT scans during the first 2 years was 2.0 (IQR, 1.2–2.5) and 0.0 (IQR, 0–0.5) in the screening and nonscreening groups, respectively. Thirty (20.3%) patients developed brain metastases during the first 2 years. The cumulative brain metastasis incidence was significantly higher in patients undergoing screening (30.6% vs. 12.3%, Gray’s P = 0.004), but symptomatic brain metastases were significantly lower in patients undergoing screening (0% vs. 9.5%, Gray’s P = 0.012). Patients undergoing screening had better preserved performance status at brain metastasis diagnosis (P = 0.002) and a numerical trend toward fewer brain metastases (P = 0.057). Treatment patterns after brain metastasis diagnosis were similar, although whole-brain radiotherapy was used less often in the screening group (14.3% vs. 44.4%, P = 0.073).Conclusions:Brain screening with CT scans was associated with fewer symptomatic brain metastases and better performance status at brain metastasis diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Purpose:According to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC) because of high risk of developing brain metastases. However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic brain metastases in patients with HER2+ mBC.Experimental Design:Consecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab–pertuzumab plus taxane (2014–2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurologic symptoms during the first 2 years after diagnosis.Results:Among 148 identified patients, 73 underwent brain screening and 75 did not. The median number of annual brain CT scans during the first 2 years was 2.0 (IQR, 1.2–2.5) and 0.0 (IQR, 0–0.5) in the screening and nonscreening groups, respectively. Thirty (20.3%) patients developed brain metastases during the first 2 years. The cumulative brain metastasis incidence was significantly higher in patients undergoing screening (30.6% vs. 12.3%, Gray’s P = 0.004), but symptomatic brain metastases were significantly lower in patients undergoing screening (0% vs. 9.5%, Gray’s P = 0.012). Patients undergoing screening had better preserved performance status at brain metastasis diagnosis (P = 0.002) and a numerical trend toward fewer brain metastases (P = 0.057). Treatment patterns after brain metastasis diagnosis were similar, although whole-brain radiotherapy was used less often in the screening group (14.3% vs. 44.4%, P = 0.073).Conclusions:Brain screening with CT scans was associated with fewer symptomatic brain metastases and better performance status at brain metastasis diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
OS after brain metastasis diagnosis according to brain screening practice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
OS after brain metastasis diagnosis according to brain screening practice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Flow diagram of the study cohort.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Flow diagram of the study cohort.
- Open Access
- 13 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (9) , OF1-OF9
Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Purpose: According to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC) because of high risk of developing brain metastases. However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic brain metastases in patients with HER2+ mBC. Experimental Design: Consecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab–pertuzumab plus taxane (2014–2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurologic symptoms during the first 2 years after diagnosis. Results: Among 148 identified patients, 73 underwent brain screening and 75 did not. The median number of annual brain CT scans during the first 2 years was 2.0 (IQR, 1.2–2.5) and 0.0 (IQR, 0–0.5) in the screening and nonscreening groups, respectively. Thirty (20.3%) patients developed brain metastases during the first 2 years. The cumulative brain metastasis incidence was significantly higher in patients undergoing screening (30.6% vs. 12.3%, Gray’s P = 0.004), but symptomatic brain metastases were significantly lower in patients undergoing screening (0% vs. 9.5%, Gray’s P = 0.012). Patients undergoing screening had better preserved performance status at brain metastasis diagnosis (P = 0.002) and a numerical trend toward fewer brain metastases (P = 0.057). Treatment patterns after brain metastasis diagnosis were similar, although whole-brain radiotherapy was used less often in the screening group (14.3% vs. 44.4%, P = 0.073). Conclusions: Brain screening with CT scans was associated with fewer symptomatic brain metastases and better performance status at brain metastasis diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.
- 13 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (9) , OF1-OF9
Open AccessProactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Purpose: According to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC) because of high risk of developing brain metastases. However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic brain metastases in patients with HER2+ mBC. Experimental Design: Consecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab–pertuzumab plus taxane (2014–2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurologic symptoms during the first 2 years after diagnosis. Results: Among 148 identified patients, 73 underwent brain screening and 75 did not. The median number of annual brain CT scans during the first 2 years was 2.0 (IQR, 1.2–2.5) and 0.0 (IQR, 0–0.5) in the screening and nonscreening groups, respectively. Thirty (20.3%) patients developed brain metastases during the first 2 years. The cumulative brain metastasis incidence was significantly higher in patients undergoing screening (30.6% vs. 12.3%, Gray’s P = 0.004), but symptomatic brain metastases were significantly lower in patients undergoing screening (0% vs. 9.5%, Gray’s P = 0.012). Patients undergoing screening had better preserved performance status at brain metastasis diagnosis (P = 0.002) and a numerical trend toward fewer brain metastases (P = 0.057). Treatment patterns after brain metastasis diagnosis were similar, although whole-brain radiotherapy was used less often in the screening group (14.3% vs. 44.4%, P = 0.073). Conclusions: Brain screening with CT scans was associated with fewer symptomatic brain metastases and better performance status at brain metastasis diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.